


I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 11th day of November, 2005.



By Carol A. Senn  
(Signature of person mailing)

Carol A. Senn  
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: :  
DANILO GIRIBONE, ET AL. :

APPLICATION NO.: 10/540,081 ✓ : Examiner: Not Yet Assigned

FILING DATE: JUNE 16, 2005 : Group Art Unit: 1614

TITLE: STABLE ISOTOPE-LABELED :  
CAMPTOTHECIN DERIVATIVES :

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicants, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicants belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO/FB/A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12). A copy of the International Search Report from counterpart International Application No. PCT/EP03/14801 is also enclosed.

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.A prompt and favorable response is earnestly solicited.

Respectfully submitted,

David L. Kershner

David L. Kershner  
Attorney for Applicant(s)  
Reg. No. 53,112

Date: November 11, 2005

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212) 733-0538

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>									ATTY. DOCKET NO. PC27365						SERIAL NO. 10/540,081										
									APPLICANT DANILO GIRIBONE, ET AL.																
									FILING DATE JUNE 16, 2005						GROUP 1614										
U.S. PATENT DOCUMENTS																									
EXAMINER INITIAL								DOCUMENT NUMBER		DATE		NAME		CLASS		SUBCLASS		FILING DATE IF APPROPRIATE							
FOREIGN PATENT DOCUMENTS																									
DOCUMENT NUMBER									DATE		COUNTRY		CLASS		SUBCLASS		TRANSLATION								
																	YES NO								
WO		0		4		0		5		6		3		9		8		7/8/04		PCT					
WO				0		1		2		1		2		1		9		2/29/01		PCT					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																									
						Slatter, J.G., et al., "Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) following I.V. Infusion of [ <sup>14</sup> C]CPT-11 in Cancer Patients", Drug Metabolism & Disposition; 2000, Vol. 28, No. 4, pgs 423-433.																			
						Atsumi, R., et al., "Pharmacokinetics of SN-38 '(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano '3', 4':6,7'-indolizino '1,2-b'quinoline-3, 14(4H, 12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats." Biological & Pharmaceutical Bulletin, Aug. 1995, Vol. 18, No. 8, pgs 1114-1119.																			
						Hinze, H.R., et al., "Stabilities of <sup>3</sup>-H- and <sup>2</sup>-H-labelled camptothecins", Journal of Labelled Compounds and Radiopharmaceuticals, 1996, Vol. 38, No. 8, pgs.733-742.																			
						Ronman, P.E., et al., "The Preparation of Tritium Labeled Camptothecin and Deuterium Labeled Camptothecin", Journal of Labelled Compounds and Radiopharmaceuticals, 1981, Vol. 18, No. 3, pgs 319-330.																			
						Emerson, D.L., et al., "Antitumor efficacy, pharmacokinetics, and biodistribution of NX211:a low clearance liposomal formulation of lurtotecan". Clinical Cancer Research, July 2000, Vol. 6, No. 7, pgs 2903-2912.																			
						Gabr, A., et al., "Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH"., Cancer Research, Nov. 1997, Vol. 57, No. 21, pgs 4811-4816																			
						Nicholas, A.W., et al., "Synthesis of position-specific tritium-labeled 20(S)-camptothecin, 9-amino-20(S)-camptothecin, and 10, 11-methylenedioxy-20(S)-camptothecin", Journal of Labelled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 9, pgs 839-848																			
EXAMINER				DATE CONSIDERED																					
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																									

Conforms with FORM PTO-FB-A820